VIDEO: Psoriasis therapies continue to improve, expand

CLEVELAND — At the Medical Dermatology Therapy Update II, Andrew Blauvelt, MD, MBA, gave an update on available psoriasis therapies and those on the horizon.

In this video, Blauvelt, president of the Oregon Medical Research Center, explained interleukin (IL)-17, IL-13 and tumor necrosis factor blockers currently on the market and which patients are best suited to which treatments, as well as an overview of two drugs in development to target new psoriasis pathways.